Abstract
In numerous situations stroke physicians face a lack of evidence during their daily practice. In this report the authors address some of the difficult treatment decisions encountered in acute therapy and secondary prevention. Examples include off-label thrombolysis and prevention in high-risk situations. The available data from trials and registries are discussed, and personal views and recommendations are expressed.
MeSH terms
-
Age Factors
-
Aged
-
Aged, 80 and over
-
Antihypertensive Agents / adverse effects
-
Antihypertensive Agents / therapeutic use
-
Atrial Fibrillation / complications
-
Atrial Fibrillation / drug therapy
-
Atrial Fibrillation / mortality
-
Blood Glucose / metabolism
-
Cerebral Hemorrhage / drug therapy
-
Cerebral Hemorrhage / mortality
-
Clinical Trials as Topic
-
Diagnosis, Differential
-
Endarterectomy, Carotid
-
Epilepsy / diagnosis
-
Evidence-Based Medicine
-
Humans
-
Hypertension / complications
-
Hypertension / drug therapy
-
Hypertension / mortality
-
International Normalized Ratio
-
Off-Label Use
-
Phenprocoumon / adverse effects
-
Phenprocoumon / therapeutic use
-
Platelet Aggregation Inhibitors / adverse effects
-
Platelet Aggregation Inhibitors / therapeutic use
-
Registries
-
Risk Factors
-
Secondary Prevention
-
Stroke / mortality
-
Stroke / prevention & control
-
Stroke / therapy*
-
Survival Analysis
-
Thrombolytic Therapy / adverse effects
-
Thrombolytic Therapy / methods
-
Treatment Outcome
Substances
-
Antihypertensive Agents
-
Blood Glucose
-
Platelet Aggregation Inhibitors
-
Phenprocoumon